CGEM
$13.44
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States.
Intraday
Recent News
Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data
Cullinan Therapeutics (NASDAQ:CGEM) outlined a milestone-heavy roadmap during a presentation at Leerink Partners’ Annual Healthcare Conference in Miami, with management emphasizing 2026 as a potentially “defining year” driven by multiple clinical readouts across its pipeline. Chief Executive Officer
Cullinan Therapeutics: Q4 Earnings Snapshot
CAMBRIDGE, Mass. AP) — Cullinan Therapeutics, Inc. CGEM) on Tuesday reported a loss of $50.7 million in its fourth quarter.
Cullinan Therapeutics Maps 2026 Data Catalysts for Autoimmune CLN-978, AML CLN-049 at TD Cowen Conference
Cullinan Therapeutics (NASDAQ:CGEM) executives highlighted upcoming clinical milestones for the company’s two high-priority T-cell engager programs during remarks at the 46th Annual TD Cowen Healthcare Conference, pointing to multiple data readouts in autoimmune disease in 2026 and an expansion plan
Cullinan Therapeutics Touts 2026 “Defining Year” as T-Cell Engager, Zipalertinib Catalysts Near
Cullinan Therapeutics (NASDAQ:CGEM) executives highlighted multiple upcoming catalysts across the company’s oncology and autoimmune portfolio during a presentation at Citi’s Virtual Oncology Leadership Summit, with management calling 2026 a “defining year” for the company. CEO Nadim Ahmed and Chief
TheStreet Pro Analysts Say, “It’s a Stock Picker’s Market – Here Are 4 to Consider”
This market is anything but easy. One day, we’re setting a new high and the next day, we might be down 2%. That’s volatility for ya. Not only volatility, but there’s also lots of sector rotation happening. The stocks that are up this year are, generally, not the ones that have been hot over the last few years. The Magnificent 7 aren’t looking so magnificent in 2026. NVIDIA (NVDA) is basically flat, Microsoft (MSFT) is off 18%, Tesla (TSLA) is down 9%. I could go on… What’s doing well? As we’ve d